DDInter623 DDInter255
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Efalizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) binds {v} (Gene) GSTA2
GSTA2 {u} (Gene) is bound by {v} (Compound) Busulfan
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisone
Prednisone {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Busulfan
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisone
Prednisone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Busulfan
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) MAPK1IP1L
MAPK1IP1L {u} (Gene) is downregulated by {v} (Compound) Busulfan
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisone
Prednisone {u} (Compound) upregulates {v} (Gene) SSBP2
SSBP2 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} (Compound) downregulates {v} (Gene) PARP1
PARP1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Bexarotene {u} (Compound) causes {v} (Side Effect) Dermatitis bullous
Dermatitis bullous {u} (Side Effect) is caused by {v} (Compound) Busulfan
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Busulfan
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludarabine
Fludarabine {u} (Compound) binds {v} (Gene) DCK
DCK {u} (Gene) is downregulated by {v} (Compound) Busulfan
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} (Compound) downregulates {v} (Gene) EBNA1BP2
EBNA1BP2 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Efalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) binds GSTA2 (Gene) and GSTA2 (Gene) is bound by Busulfan (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Busulfan (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Busulfan (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate (Compound) upregulates MAPK1IP1L (Gene) and MAPK1IP1L (Gene) is downregulated by Busulfan (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) upregulates SSBP2 (Gene) and SSBP2 (Gene) is upregulated by Busulfan (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate (Compound) downregulates PARP1 (Gene) and PARP1 (Gene) is upregulated by Busulfan (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene (Compound) causes Dermatitis bullous (Side Effect) and Dermatitis bullous (Side Effect) is caused by Busulfan (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Busulfan (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine (Compound) binds DCK (Gene) and DCK (Gene) is downregulated by Busulfan (Compound)
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is downregulated by Busulfan (Compound)